November 10, 2021
Weekly Share Classes Update
Please find attached Makor’s European Weekly Share Class Report.
As usual, we focus in Europe on Share Classes with a liquidity for each leg > €3m and a Spread > 2%.
We elaborate further in this note and we have additional analysis available on request.
Focus list:
1. RO SW - ROG SW
2. INDUA SS - INDUC SS
3. VOW3 GY - VOW GY
4. EPIB SS - EPIA SS
5. BMW3 GY - BMW GY
6. HEN3 GY - HEN GY
7. SSABA SS - SSABB SS
8. TITR IM - TIT IM
9. SCHA NO - SCHB NO
10. UHRN SW - UHR SW
11. RDSA LN - RDSB LN
12. SRT3 GY - SRT GY
13. ATCOB SS - ATCOA SS
14. MAERSKA DC - MAERSKB DC
15. LISN SW - LISP SW
16. VOLVA SS - VOLVB SS
We are available at your convenience if you need any additional details
![]()
Makor Capital
11 Menachem Begin St., 26th FL
Ramat Gan 52681
ISRAEL
Tel +972 3 5453 762Fax +972 3 7162 680
Research Disclaimer
This publication has been prepared by Makor Capital Limited (“Makor Capital”) and is intended for professional or qualified investors only. Makor Securities London Ltd (“Makor Securities”)is distributing this material to its clients who are Eligible Counterparties or Professional Clients under FCA Rules. It may also be disseminated to persons who are Investment Professionals within the meaning of the Financial Services and Markets Act 2000 (Financial Promotion Order 2005). In the United States, Makor Capital only distributes this material to major US institutional investors (as that term is defined in Rule 15a-6 of the Securities and Exchange Act of 1934) and to SEC-registered broker-dealers or banks acting in a broker–dealer capacity. This material is not intended for distribution to any other persons and should not be redistributed. If you do not fall into any of these categories you should disregard it.
This material is a marketing communication. It is not investment research and has not been prepared in accordance with legal requirements designed to promote the independence of investment research. It is not subject to any prohibition on dealing ahead of the dissemination of investment research under U.K. law. This material is not a research report and is not intended to be a research report as defined under U.S. securities laws and regulations. This material is not intended to provide information reasonably sufficient upon which to base any investment decision.
This material does not take into account the particular investment objectives, financial situation or needs of individual clients or other recipients. Before acting on this material, clients and other recipients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.
This material should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action.
In the United States, Makor Capital does not offer securities services to U.S. persons except pursuant to SEC Rule 15a-6 only to major US institutional investors and SEC registered broker-dealers or banks acting in a broker–dealer capacity. Transactions in the United States must be effected through the U.S. broker-dealer, Oscar Gruss & Son Incorporated. Oscar Gruss & Son has not prepared, reviewed or distributed this material.
Some of this material is produced by providers which Makor Securities believes to be reliable, but Makor Securities does not warrant or represent (expressly or impliedly) that it is accurate, complete, not misleading or as to its fitness for the purpose intended and it should not be relied upon as such.
Opinions expressed will be the current opinions of those producing this material as of the date appearing on this material only. We expect those producing the material in this publication to update it on a timely basis but can give no undertaking that they will do so and regulatory compliance or other reasons may prevent them from doing so (or us from disseminating updated material).
Members and employees of Makor Securities London Ltd, employees of Makor Capital, Makor Capital Markets may from time to time have long or short positions in securities, warrants, futures, options, derivatives or other financial instruments referred to in this material. For Makor Securities, this information is set out in our Conflicts of Interest Policy which is available on request. Policies for the production of research from other research providers are available on request. Unless otherwise stated, share prices provided within this material are as at the close of business on the day prior to the date of the material.
Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without prior consent. This material is issued for general information and discussion purposes only. None of Makor Securities, Makor Capital, Makor Capital Markets accepts liability whatsoever for any direct, indirect or consequential loss or damage of any kind arising out of the use of all or any of this material.
The services, securities and investments discussed in this material may not be available to, nor are suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and it should be noted that investment involves risk, including the risk of capital loss. Past performance is no guide to future performance. In relation to securities denominated in foreign currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable.
All investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and it should be noted that investment involves risk, including the risk of capital loss. Past performance is no guide to future performance. In relation to securities denominated in foreign currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable.
Entities
Makor Securities London Ltd is authorised and regulated by the Financial Conduct
Authority (FCA registration number 625054)
Makor Capital, company number 514456466, is incorporated in Israel and is a 100% held
subsidiary of Makor Holdings Pte Ltd incorporated in Singapore.
Makor Capital Markets SA, company number CH-660.2.999.011-0 is incorporated in Switzerland
and is also a 100% held subsidiary of Makor Holdings Pte Ltd.
Having trouble viewing this email? Click here
Powered by
* Bakkafrost Raised to Hold at Pareto Securities; PT 620 kroner
>>> Down
* OVB Holding Cut to Accumulate at SRC Research; PT 28 euros
>>> Initiation
* Oxford Nanopore Rated New Neutral at Citi; PT 660 pence
>>> Call
* UBS Sees Japan, European Equities Catching Up With U.S. in 1H22
- Infineon (IFX TH) +2.1%
- Infineon Sees ‘Strong’ 2022 With Auto Segment Leading Sales (1)
- Prosus (1TY TH) +1.7%
- *TENCENT SHARES JUMP AS MUCH AS 4.6% AHEAD OF EARNINGS
- Rolls-Royce (RRU TH) +1%
- Atlas Copco (ACO2 TH) +0.8%
- Equinor (DNQ TH) +0.8%
- Shell (R6C TH) +0.7%
- Brent Near $85 a Barrel Shows Oil Risk Remains Skewed to Upside
- Allianz (ALV TH) +0.7%
- Allianz 3Q Operating Profit Beats Estimates
- Evolution (E3G1 TH) +0.6%
- Siemens Energy (ENR TH) -0.5%
- Siemens Energy Vows to Improve on Profit After Losses Narrow
- Just Eat Takeaway (T5W TH) -0.7%
- Watch Online Food Delivery Stocks on DoorDash Beat, Wolt Deal
- Rheinmetall (RHM TH) -0.7%
- MTU Aero (MTX TH) -0.8%
- AB InBev (1NBA TH) -1%
- Puma (PUM TH) -1.7%
- Adidas (ADS TH) -3.2%
- Adidas Hit by Supply-Chain Woes as Asia Snags Delay Shoe Sales
F L A S H | Salvatore Ferragamo SpA (SFER.MI) | Neutral
Mixed performance in a seasonally light quarter; focus on Aug/Sep Retail slowdown and management's worries about China in Nov
CITI'S TAKE
In what is traditionally the smallest quarter of the year for Ferragamo, the marginal 3Q21 sales beat and £5m EBIT beat (£19m vs. cons. £14m and twice 3Q19 level) are unlikely to drive the same enthusiasm seen after 2Q (strong earnings beat and double-digit EPS ugprades). While Ferragamo remains focused on rejuvenating sales while maintaining costs under control, the analyst call highlighted a significant slowdown in Aug/Sep Retail LFL (2Y down double-digit estimated) vs. July (broadly flat vs. 2019), with an improvement in October but renewed concerns at the beginning of November on China/Asia's COVID resurgence. All in all, we expect low-single-digit percentage increase in cons. FY21E EBIT and unchanged FY22E. This should lead to a muted share price reaction, yet we see potential support from continued share price underperformance (+26% YTD vs. luxury sector +40%) and the imminent arrival of high-calibre CEO Marco Gobbetti. Neutral rating maintained, TP €20.0.
Key 3Q21 numbers — 1) Sales of €261m, ~2% above VA consensus (€256m), up 17% YoY in constant FX (cons. +11%). On a 2Y stacked basis, sales were down only 4% (cons. -9%) including Retail -5% (cons. -3%, 2Q21 -9%) with sequential MoM deterioration in August and early Sep (vs. July flat) and improvements at the end of the quarter; and Wholesale -2% (cons. -22%, 2Q21 -41%); 2) EBIT of €19m (consensus €14m), with an EBIT margin of 7.1% (cons. 5.5%) compared to ~4% in 3Q19. This reflects: i) gross margin of 65.4% (cons. 66.0%) or 70bp above 3Q19 (64.7%) from higher full-price sales, lower provision for obsolescence and favourable channel mix; and ii) continued cost reduction (-14% vs. 3Q19 and +13% YoY) driven by headcount reduction, rents renegotiation, and lower consulting fees; 3) Net income of €7m (consensus €4m); and 4) Net cash position (ex-IFRS 16) of €265m (vs. €75m in 3Q20 and €139m at the end of FY20) largely reflecting improved earnings, a ~20% YoY decrease in inventories (constant FX, excluding fragrances), and limited capex (€26m).
2Q21 segment reporting (2-year stack, constant FX) — By region: Europe -26% (cons. -26%, 2Q21 -39%); strong beat in North America +26% (cons. +1%, 2Q21 -3%); Asia ex-Japan -4% (cons. -10%, 2Q21 -22%) reflecting August softness in China and weak travel retail; Japan -20% (cons. -14%, 2Q21 -31%) impacted by August lockdowns and travel restrictions; and LatAm +12% (cons. -11%, 2Q21 +38%). By product: Footwear -4% (cons. -9%, 2Q21 -23%); Leather Goods flat (cons. -7%, 2Q21 -15%); Clothing -1% (cons. -12%, 2Q21 -7%); and Silk/Other Accessories -12% (cons. -20%, 2Q21 -21%).
Waiting for Mr Gobbetti — There will be legitimate ambitions for a turnaround from impending CEO Marco Gobbetti (starting Jan22) and following recent senior appointments (COO and heads of US and Europe). At 61 years old, this will likely be Mr Gobbetti’s last senior executive role and we believe he will be highly energised to wake the Ferragamo sleeping beauty, while prior attempts have produced mixed results. We see the return of a strong creative director function as very likely under Mr Gobbetti.
Implications — Latest VA consensus includes: 1) FY21E sales of €1.13bn (2Y constant FX -15%) implying 4Q21E sales of €344m (-10% constant FX vs 2019); and 2) FY21E EBIT of €111m (-26% vs 2019, 9.8% margin broadly flat vs 2019) implying 4Q21E EBIT of €27m (~40% below 4Q19) implying margin of 7.7% (-400bp vs. 2019). Given the slight 3Q21 sales and EBIT beat, cons. 4Q21E/FY21E revenue and EBIT look conservative, however management’s expressed concerns on China at the start of November which could limit earnings momentum following strong earnings upgrades post 1H21. We expect low-single-digit percentage increase in cons. FY21E EBIT and unchanged FY22E. We expect muted share price reaction yet acknowledge potential support from continued share price underperformance (+26% YTD vs. luxury sector +40%) and the arrival of high-calibre CEO Marco Gobbetti. Shares trade on a ~45x FY23E P/E close to twice sector average ex-Hermes. Neutral rating maintained, TP €20.0.
Neutral
Price (09 Nov 21 17:30)
€19.98
Expected share price return
0.1%
Target price
€20.00
Expected dividend yield
1.0%
Market Cap
€3,372M
US$3,908M
Expected total return
1.1%
Salvatore Ferragamo SpA (EUR)
Year to 31 Dec
2019A
2020A
2021E
2022E
2023E
Sales (€M)
1,377.3
915.8
1,147.9
1,270.4
1,364.8
Net Income (€M)
87.3
-31.8
13.0
50.0
73.7
Diluted EPS (€)
0.52
-0.19
0.08
0.30
0.44
Diluted EPS (Old) (€)
0.52
-0.19
0.08
0.30
0.44
PE (x)
38.7
-106.2
259.1
67.5
45.7
EV/EBITDA (x)
10.5
19.3
15.6
12.4
10.7
DPS (€)
0.00
0.00
0.06
0.20
0.25
Net Div Yield (%)
na
na
0.3
1.0
1.3
Source: Company Reports and dataCentral, Citi Research.


